Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

23.46
+0.09000.39%
Post-market: 23.43-0.0310-0.13%19:40 EDT
Volume:1.95M
Turnover:45.46M
Market Cap:1.63B
PE:-5.81
High:23.72
Open:23.72
Low:22.71
Close:23.37
52wk High:71.50
52wk Low:8.73
Shares:69.37M
Float Shares:57.53M
Volume Ratio:0.22
T/O Rate:3.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0399
EPS(LYR):-3.4602
ROE:-157.61%
ROA:-15.72%
PB:5.02
PE(LYR):-6.78

Loading ...

RBC Cuts Price Target on uniQure to $48 From $65, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Yesterday

Uniqure N.v. : RBC Cuts Target Price to $48 from $65

THOMSON REUTERS
·
Yesterday

Barclays Sticks to Their Buy Rating for uniQure (QURE)

TIPRANKS
·
Sep 30

uniQure weakness creates attractive opportunity, says Wells Fargo

TIPRANKS
·
Sep 30

RBC says uniQure’s four-year HD data mixed, stock reaction ‘overdone’

TIPRANKS
·
Sep 30

Top Midday Decliners

MT Newswires Live
·
Sep 30

uniQure ‘mixed’ four-year data complicates durability case, says H.C. Wainwright

TIPRANKS
·
Sep 30

France's MaaT Pharma H1 Operating Loss Widens on Higher R&D Costs

Reuters
·
Sep 30

uniQure falls -38.4%

TIPRANKS
·
Sep 30

Crude Oil Down 1%; US Job Openings Fall In August

Benzinga Earnings
·
Sep 30

U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle

Reuters
·
Sep 29

Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings

Benzinga Earnings
·
Sep 29

Sector Update: Healthcare Stocks Advance Pre-Bell Tuesday

MT Newswires Live
·
Sep 29

UniQure Stock Drops After Huntington's Drug Results Disappoint at 4-Year Mark

Dow Jones
·
Sep 29

UniQure Says Additional AMT-130 Data Show Weaker Results at 4 Years; Shares Tumble

MT Newswires Live
·
Sep 29

uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

GlobeNewswire
·
Sep 29

Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)

TIPRANKS
·
Sep 03

uniQure submits biologics license application to FDA for ifezuntirgene inilparvo

TIPRANKS
·
Sep 02

Uniqure N.v. : William Blair Resumes Coverage with Outperform Rating

THOMSON REUTERS
·
Sep 02

uniQure Seeks FDA Priority Review for Huntington’s Gene Therapy AMT-130 BLA

Reuters
·
Sep 02